Is There a Link Between Liraglutide and Pancreatitis? A Post Hoc Review of Pooled and Patient-Level Data From Completed Liraglutide Type 2 Diabetes Clinical Trials
The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To report the incidence of pancreatitis in type 2 diabetes trials of liraglutide and details of all pancreatitis cases. RESEARCH DESIGN AND METHODS: Data from Novo Nordisk–sponsored trials with liraglutide (phase 2 and 3; NN2211 identifiers) completed by 19 April 2013 were pooled. All pancreatitis cases were reviewed. RESULTS: Total exposure to liraglutide and active comparators was 5,021 and 1,354 patient-years, respectively (n = 6,345 and 1,846, respectively). Eight cases of acute pancreatitis (AP) with liraglutide and one with any comparator (glimepiride) were found. The incidence of AP was 1.6 cases/1,000 patient-years exposure (PYE) for liraglutide vs. 0.7 cases/1,000 PYE for total active comparators. One of the eight AP cases reported with liraglutide did not meet diagnostic criteria for AP. In six of these eight cases, recognized risk factors for AP were present and/or the onset of AP occurred >6 months after liraglutide initiation. All patients were receiving multiple medications. Four cases of chronic pancreatitis (CP) with liraglutide and none with comparators were found. One of these four cases fulfilled diagnostic criteria for CP; these criteria were not met or information was missing in the remaining three. CONCLUSIONS: Based on the small number of cases observed, the incidences of reported AP and CP were numerically greater with liraglutide than with comparators. Not all cases fulfilled diagnostic criteria, and confounding variables were present in 75% of the AP cases with liraglutide therapy, precluding firm conclusions.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Higher levels of lipase and amylase were observed in the liraglutide group, a finding that is similar to results in other studies.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [24]
In the citing paper
“There has been considerable interest in a potential association between the use of GLP-1–receptor agonists and pancreatitis and pancreatic cancer, although there is no consistent preclinical, pharmacovigilance, or epidemiologic evidence to date.”
From Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (2016) · cites this paper as [24]
In the citing paper
“However, some rare cases of acute pancreatitis and neoplasms have been reported [53–55]”
From Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control (2016) · cites this paper as [53]
In the citing paper
“In addition, GLP-1RAs use may be associated with an increased risk of acute pancreatitis and thyroid cancer, and the FDA has warned the public about these AEs (10–12).”
From Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system (2022) · cites this paper as [10]
Citations
Cites
R: A Language and Environment for Statistical Computing
R Core Team (2025) · doi:10.32614/r.manuals · Cited by 352,181
Banks, P. A., Bollen, T. L., Dervenis, C., Gooszen, H. G., Johnson, C. D., Sarr, M. G., Tsiotos, G. G., & Vege, S. S. (2013) · Gut · doi:10.1136/gutjnl-2012-302779 · Cited by 7,187
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“50) compared with placebo, with a numerical imbalance between arms (47,48).”
BackgroundPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944
Drug-Induced Acute Pancreatitis: An Evidence-Based Review
Badalov, N., Baradarian, R., Iswara, K., Li, J., Steinberg, W., & Tenner, S. (2007) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.11.023 · Cited by 589 · cited 1×
“There is a substantial body of literature on drug-induced acute pancreatitis (40).”
BackgroundSelf-citationPancreatic safety of incretin-based drugs–FDA and EMA assessment
Egan, A. G., Blind, E., Dunder, K., de Graeff, P. A., Hummer, B. T., Bourcier, T., & Rosebraugh, C. (2014) · New England Journal of Medicine · doi:10.1056/nejmp1314078 · Cited by 498
Singh, S., Chang, H.-Y., Richards, T. M., Weiner, J. P., Clark, J. M., & Segal, J. B. (2013) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2013.2720 · Cited by 467
Butler, A. E., Campbell-Thompson, M., Gurlo, T., Dawson, D. W., Atkinson, M., & Butler, P. C. (2013) · Diabetes · doi:10.2337/db12-1686 · Cited by 457
Increased Risk of Acute Pancreatitis and Biliary Disease Observed in Patients With Type 2 Diabetes
Noel, R. A., Braun, D. K., Patterson, R. E., & Bloomgren, G. L. (2009) · Diabetes Care · doi:10.2337/dc08-1755 · Cited by 435
Pancreatic Safety of Incretin-Based Drugs — FDA and EMA Assessment
(2014) · New England Journal of Medicine · doi:10.1056/nejmx140026 · Cited by 372
Acute Pancreatitis in Type 2 Diabetes Treated With Exenatide or Sitagliptin
Garg, R., Chen, W., & Pendergrass, M. (2010) · Diabetes Care · doi:10.2337/dc10-0482 · Cited by 322
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Butler, P. C., Elashoff, M., Elashoff, R., & Gale, E. A. M. (2013) · Diabetes Care · doi:10.2337/dc12-2713 · Cited by 296
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254 · cited 1×
“17) with incretinbased therapies versus control; estimates calculated by incretin therapy class (GLP1 receptor agonists or DPP-4 inhibitors) showed similar results (23).”
ResultMarso, S. P., Poulter, N. R., Nissen, S. E., Nauck, M. A., Zinman, B., Daniels, G. H., Pocock, S., Steinberg, W. M., Bergenstal, R. M., Mann, J. F. E., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.07.012 · Cited by 245 · cited 2×
“The long-term cardiovascular outcome trial LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome ResultsdA Long Term Evaluation) (46) in which 9,340 patients with type 2 diabetes are enrolled is expected to provide information regarding safety of up to 5 years’ liraglutide exposure by…”
BackgroundSelf-citationSafety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Monami, M., Dicembrini, I., Martelli, D., & Mannucci, E. (2011) · Current Medical Research and Opinion · doi:10.1185/03007995.2011.602964 · Cited by 217
Girman, C. J., Kou, T. D., Cai, B., Alexander, C. M., O’Neill, E. A., Williams‐Herman, D. E., & Katz, L. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01231.x · Cited by 212
A Critical Analysis of the Clinical Use of Incretin-Based Therapies
Nauck, M. A. (2013) · Diabetes Care · doi:10.2337/dc12-2504 · Cited by 205
Alves, C., Batel-Marques, F., & Macedo, A. F. (2012) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.09.008 · Cited by 186
Acute Pancreatitis in Association With Type 2 Diabetes and Antidiabetic Drugs
Gonzalez-Perez, A., Schlienger, R. G., & Rodríguez, L. A. G. (2010) · Diabetes Care · doi:10.2337/dc10-0842 · Cited by 139
Raschi, E., Piccinni, C. P., Poluzzi, E., Marchesini, G., & Ponti, F. D. (2011) · Acta Diabetologica · doi:10.1007/s00592-011-0340-7 · Cited by 137
Lando, H. M., Alattar, M., & Dua, A. P. (2012) · Endocrine Practice · doi:10.4158/ep11290.or · Cited by 102
Risk of pancreatitis in patients treated with incretin-based therapies
Meier, J. J., & Nauck, M. A. (2014) · Diabetologia · doi:10.1007/s00125-014-3231-y · Cited by 101
Funch, D., Gydesen, H., Tornøe, K., Major‐Pedersen, A., & Chan, K. A. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12230 · Cited by 81
Incretin Therapy and Islet Pathology: A Time for Caution
Kahn, S. E. (2013) · Diabetes · doi:10.2337/db13-0520 · Cited by 57
Acute Pancreatitis Associated with Liraglutide
Lee, P. H., Stockton, M. D., & Franks, A. S. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p714 · Cited by 57
Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies
Bonner‐Weir, S., In't Veld, P. A., & Weir, G. C. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12257 · Cited by 54
Pancreatitis: A Potential Complication of Liraglutide?
Franks, A. S., Lee, P. H., & George, C. M. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q789 · Cited by 34 · cited 1×
“At least 11 case reports suggested a relationship between liraglutide and pancreatitis, highlighting pancreatitis as a potential complication of therapy and suggesting caution when prescribing liraglutide (17).”
BackgroundSteinberg, W. M., DeVries, J. H., Wadden, T. A., Jensen, C. B., Svendsen, C. B., & Rosenstock, J. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)63296-x · Cited by 26
Self-citationGurney, K., Malloy, Shan, S., Yan, Y., & Chen (2012) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s34241 · Cited by 22
422 Elevated Serum Lipase Activity in Adults With Type 2 Diabetes and No Gastrointestinal Symptoms
Steinberg, W. M., Rosenstock, J., DeVries, J. H., Thomsen, A. B., Svendsen, C. B., & Wadden, T. A. (2012) · Gastroenterology · doi:10.1016/s0016-5085(12)60358-8 · Cited by 12
Self-citationLiraglutide pancreatitis: The ABCD nationwide liraglutide audit
Ryder, R. E. J., Thong, K. Y., Blann, A. D., Phillips, S., Barwell, N., Kelly, C., Semple, C., CULL, M. L., Gupta, P. S., & contributors, F. T. A. N. L. A. (2013) · The British Journal of Diabetes · doi:10.1177/1474651413502685 · Cited by 11
Comment: Acute Pancreatitis Associated with Liraglutide
Steinberg, W. M. (2011) · Annals of Pharmacotherapy · doi:10.1345/aph.1p714a · Cited by 8 · cited 2×
“A short statement on six of the cases included in the case reviews was included in a letter to The Annals of Pharmacotherapy (35).”
BackgroundSelf-citationAssessment of acute pancreatitis in liraglutide type 2 diabetes trials
Jensen, T. M., Saha, K., & Steinberg, W. M. (2013) · Pancreatology · doi:10.1016/j.pan.2012.12.186 · Cited by 5 · cited 1×
“Parts of this study were presented at the 2012 Joint Meeting of the American Pancreatic Association and International Association of Pancreatology, Miami, FL, 31 October–3 November 2012 (49).”
MethodSelf-citation
Research works printed but not linked: 1
- Gourdy, 2013, Effectiveness and persistence with liraglutide among patients with type 2 diabetes. One year data from EVIDENCE: a 2-year, prospective, follow up, post-marketing study (Abstract), Diabetologia, 56, S369
Cited by
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationAnti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
“However, some rare cases of acute pancreatitis and neoplasms have been reported [53–55]; thus the establishment of safety of GLP-1-based therapy should be validated by sufficient further studies.”
BackgroundNauck, M. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12591 · Cited by 429
“Although few cases of pancreatitis were reported in clinical trials with liraglutide, the incidence among patients receiving liraglutide was greater than those among patients receiving placebo or comparator medications [73].”
ResultMonami, M., Nreu, B., Scatena, A., Cresci, B., Andreozzi, F., Sesti, G., & Mannucci, E. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12926 · Cited by 243
“FIGURE 2 MH-OR with 95% CI for pancreatitis for GLP-1 receptor agonists vs placebo or other active comparators Study name Statistics for each study MH odds ratio and 95% CI Relative MH odds Lower Upper weight 0,16Seino 2010 ratio 0,63 0,16Zinman 2009 0,63 Diamant 2012 0,32 0,63 NCT00976937 0,34 0,63 0,36Grunberger 201…”
InfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1611289 · Cited by 195
Metadata
- Authors
- Jensen, T. M., Saha, K., & Steinberg, W. M.
- Affiliations
- UK Medical Affairs, Novo Nordisk Ltd., Gatwick, U.K.
- Novo Nordisk (Denmark) (DK)
- George Washington University (US)
- Corresponding author
- Jensen, Troels M.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-05-12
- Volume
- 38
- Issue
- 6
- Pages
- 1058-1066
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2098737080
- Cited by
- 48
- References
- 36
- Citations by year
- 2026: 1 · 2024: 3 · 2023: 3 · 2022: 3 · 2020: 4 · 2019: 6 · 2018: 4 · 2017: 6 · 2016: 8 · 2015: 10
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-08-01)
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- liraglutide, pancreatitis, acute pancreatitis, chronic pancreatitis, type 2 diabetes, GLP-1 receptor agonists, drug safety, glimepiride, risk factors, confounding
- MeSH terms
- Liraglutide, Acute Disease, Adult, Aged, Diabetes Mellitus, Type 2, Female, Humans, Hypoglycemic Agents, Male, Middle Aged, Pancreatitis, Risk Factors, Sulfonylurea Compounds, Randomized Controlled Trials as Topic, Pancreatitis, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.